KPV Peptide UK: Research Evidence in the Peptides UK Market
KPV Peptide UK: Research Evidence in the Peptides UK Market
KPV is a naturally occurring three-amino-acid fragment found at the C-terminal end of alpha-melanocyte-stimulating hormone. Laboratory and animal research has examined KPV in inflammatory signalling, intestinal transport, experimental colitis, airway epithelial responses and antimicrobial systems. Despite growing commercial interest, no controlled human exposure study has established its safety or effectiveness.
Direct Answer
KPV is the tripeptide lysine-proline-valine. It forms residues 11 to 13 at the C-terminal end of alpha-melanocyte-stimulating hormone, commonly abbreviated to alpha-MSH.
In cell experiments, KPV has altered inflammatory signalling associated with nuclear factor kappa B, mitogen-activated protein kinases and pro-inflammatory cytokines. Intestinal research indicates that the dipeptide and tripeptide transporter PepT1 can carry KPV into selected epithelial and immune cells.
Mouse studies have reported changes in chemically induced colitis and colitis-associated tumour formation. Other laboratory work has examined airway epithelial inflammation, keratinocyte signalling, cadaver-skin penetration and antimicrobial activity.
These findings are preclinical. FDA reported in 2026 that it had not identified clinical studies, pharmacokinetic studies, case reports or human exposure data for KPV by any route. No UK marketing authorisation for a KPV medicine was identified for this article.
KPV Peptide Key Points
The essential facts for interpreting KPV research without converting laboratory findings into medical claims.
What Is KPV Peptide?
KPV is one of the shortest peptide fragments studied within melanocortin biology.
The letters K, P and V are the single-letter amino-acid codes for lysine, proline and valine.
When joined in that order, they form a tripeptide containing two peptide bonds. The commonly described free peptide has an unmodified amino terminus and a carboxylic-acid terminus.
KPV occurs as the final three amino acids of alpha-MSH, whose complete 13-residue sequence is Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val.
It is frequently called alpha-MSH 11–13 because lysine, proline and valine occupy positions 11, 12 and 13 of the parent peptide.
KPV Research in the Peptides UK Market
Commercial visibility has moved ahead of controlled human research.
KPV increasingly appears in Peptides UK catalogues as a single research peptide or as one component within combinations such as KLOW.
Commercial descriptions commonly associate it with inflammatory bowel disease, intestinal permeability, eczema, psoriasis, wound healing, mast-cell conditions, Candida, immune regulation or general recovery.
These descriptions often combine findings from cell experiments, chemically induced mouse-disease models and modified peptide derivatives. They may then present the combined narrative as though KPV has been tested as a clinical treatment.
FDA’s 2026 review found that websites promoted KPV in injectable, oral, topical and nasal forms despite an absence of identified human exposure studies.
A product category does not establish clinical evidence
The presence of KPV within the Peptides UK market does not prove that a finished vial has been studied in people, manufactured to medicinal standards or shown to be suitable for personal use.
KPV and Alpha-Melanocyte-Stimulating Hormone
KPV shares part of alpha-MSH but does not reproduce the complete parent hormone.
Alpha-MSH is a 13-residue melanocortin peptide produced through processing of the larger pro-opiomelanocortin precursor.
The complete hormone participates in pigmentation, inflammatory signalling, immune regulation and other biological processes through melanocortin receptors.
Classical melanocortin-receptor activity depends strongly on the central His-Phe-Arg-Trp sequence of alpha-MSH. KPV does not contain this receptor-binding motif.
Several experiments found that KPV did not reproduce conventional melanocortin-receptor binding or cyclic-AMP signalling. Its reported inflammatory effects may therefore involve mechanisms that differ from the principal receptor pathway used by full alpha-MSH.
This distinction is one reason KPV has attracted research interest. Scientists have investigated whether some inflammatory effects can be separated from the pigmentation-related activity of the parent hormone.
KPV is not interchangeable with alpha-MSH
Sharing three residues does not give KPV the same receptor profile, tissue distribution, metabolism or biological effects as the complete 13-residue hormone.
History of KPV Research
Research developed from early studies of the C-terminal region of alpha-MSH.
Alpha-MSH Fragment Research
Researchers examined shorter sections of alpha-MSH to identify the minimum sequences associated with particular biological observations.
Inflammation Models
Early animal work reported that the C-terminal KPV sequence altered selected acute-inflammatory and contact-sensitivity responses.
Antimicrobial Experiments
Laboratory studies investigated KPV and alpha-MSH against organisms including Staphylococcus aureus and Candida albicans.
Intestinal Transport Research
Work published in 2008 examined the PepT1 transporter, inflammatory signalling in intestinal and immune cells, and chemically induced colitis in mice.
Targeted Delivery Systems
Later studies incorporated KPV into nanoparticles and other engineered systems intended to deliver the peptide to inflamed intestinal tissue.
Commercial Research Market
KPV became widely promoted online despite the continuing absence of an established human pharmacology, toxicology or clinical-efficacy programme.
KPV Molecular and Scientific Profile
Correct interpretation begins by identifying the exact peptide and chemical form.
KPV Free Peptide
The free peptide is commonly written as H-Lys-Pro-Val-OH.
Alpha-MSH 11–13
KPV corresponds to the last three residues of human alpha-MSH.
The fragment does not include the central melanocortin-receptor pharmacophore of the complete hormone.
| Common name | KPV |
|---|---|
| Full peptide name | Lysyl-prolyl-valine |
| Amino-acid sequence | Lys-Pro-Val |
| Single-letter sequence | KPV |
| Peptide length | Three amino-acid residues |
| Free-peptide formula | C16H30N4O4 |
| Free-peptide molecular weight | Approximately 342.43 g/mol |
| Acetate-associated molecular weight | Approximately 402.5 g/mol when represented with one molecule of acetic acid |
| Parent peptide | Alpha-melanocyte-stimulating hormone |
| Established human receptor | No single confirmed receptor fully explains the reported KPV effects |
KPV Free Base, KPV Acetate and Modified KPV
Similar product names may describe chemically different materials.
| Term | Simplified Description | Important Distinction |
|---|---|---|
| KPV free peptide | H-Lys-Pro-Val-OH | Unmodified amino and carboxyl termini |
| KPV acetate | KPV associated with acetate as a salt or counterion | Acetate association changes measured mass and assay calculations |
| KPV-NH₂ | C-terminally amidated derivative | Not chemically identical to natural H-Lys-Pro-Val-OH |
| KdPT | Lys-D-Pro-Thr | A separate synthetic tripeptide with different residues and stereochemistry |
| CKPV derivatives | Cysteine-containing or linked analogues | Modified experimental compounds rather than unmodified KPV |
FDA’s assessment identified inconsistent naming and chemical information across public sources and nomination documents.
One certificate may refer to KPV acetate while presenting the formula of free KPV. Another supplier may use the name KPV for a C-terminally amidated peptide.
Research involving one form should not be applied automatically to another. Terminal modification and counterion content can affect mass, charge, solubility, stability and biological behaviour.
Acetate salt is not the same as peptide acetylation
An acetate counterion is associated ionically with a peptide. N-terminal acetylation creates a covalent chemical modification. These terms should not be used interchangeably.
How Is KPV Thought to Act in Research Models?
No single mechanism has been confirmed across every experimental system.
Nuclear Factor Kappa B
Nuclear factor kappa B, usually abbreviated to NF-kappa B, regulates the expression of numerous genes associated with inflammation and immune responses.
Cell experiments reported that KPV reduced activation or nuclear signalling involving NF-kappa B under selected inflammatory conditions.
Mitogen-Activated Protein Kinases
Mitogen-activated protein kinase pathways respond to environmental stress, cytokines and growth signals.
Intestinal-cell research reported changes in MAP-kinase signalling after KPV was transported into cells through PepT1.
Pro-Inflammatory Cytokines
Studies measured changes in mediators including interleukin-8, tumour-necrosis-factor-related signalling and interleukin-1 effects.
A lower cytokine measurement in a cell system does not establish treatment of an inflammatory disease.
Melanocortin-Receptor-Independent Effects
Several experiments did not find conventional melanocortin-receptor binding or cyclic-AMP responses from KPV.
The available data therefore suggest that some reported KPV effects may occur independently of the classical receptor mechanisms used by alpha-MSH.
A pathway is not a clinical outcome
Changes in transcription factors or cytokines help researchers investigate biological mechanisms. They do not establish symptom improvement, disease remission or an acceptable human benefit-to-risk profile.
KPV and PepT1 Transport Research
PepT1 provides one proposed route by which KPV can enter intestinal and immune cells.
Peptide transporter 1, or PepT1, normally transports selected dipeptides and tripeptides across cell membranes.
PepT1 is strongly expressed in the small intestine. Its expression is normally low in the healthy colon but can increase in colonic epithelial cells during experimental or inflammatory conditions.
A 2008 study used human intestinal epithelial cell lines and a human T-cell line to investigate KPV transport.
The researchers reported that PepT1 transported KPV into the studied cells. Intracellular KPV was associated with reduced NF-kappa B and MAP-kinase activation and lower interleukin-8 secretion.
PepT1 was also important in later mouse work examining colitis-associated tumour formation.
Intestinal and Immune-Cell Research
Cell studies provide mechanistic evidence rather than proof of treatment.
Epithelial Signalling
KPV was studied in human intestinal epithelial cell lines exposed to inflammatory stimuli.
Researchers reported lower activation of selected NF-kappa B and MAPK pathways after PepT1-mediated uptake.
T-Cell Experiments
Human Jurkat T-cell systems were used to investigate peptide transport and inflammatory signalling.
These immortalised cells are research tools and do not represent the complete human immune response.
Interleukin-8 Measurements
Reduced interleukin-8 secretion was reported under selected laboratory conditions.
A cytokine concentration in a cell-culture dish is not the same as disease activity in a person.
PepT1 Dependence
Manipulation of PepT1 expression supported a role for the transporter in KPV uptake and response.
The importance of this mechanism may differ between tissues and disease states.
KPV Research in Mouse Colitis Models
The strongest frequently cited findings involve chemically induced intestinal inflammation in mice.
DSS and TNBS Models
Two commonly used experimental colitis models involve dextran sodium sulphate, abbreviated to DSS, and trinitrobenzene sulphonic acid, abbreviated to TNBS.
These chemicals produce intestinal injury and inflammation through different mechanisms. Neither model reproduces the complete immune, genetic and clinical complexity of Crohn’s disease or ulcerative colitis.
In the 2008 PepT1 study, KPV was associated with lower expression of selected inflammatory mediators and changes in disease measurements in DSS and TNBS mouse models.
A separate 2008 study also reported reduced inflammatory infiltration and myeloperoxidase activity in two mouse colitis models.
Some findings appeared at least partly independent of melanocortin-1 receptor signalling.
KPV has not been shown to treat human inflammatory bowel disease
Chemically induced mouse colitis is a preclinical research model. FDA found no clinical study in which KPV was administered to people with ulcerative colitis, Crohn’s disease or another inflammatory condition.
Colitis-Associated Cancer Research
A mouse study examined whether PepT1-dependent KPV transport altered tumour development in an inflammation-associated model.
Chronic intestinal inflammation can contribute to cancer development in particular experimental and clinical contexts.
A 2016 study investigated PepT1 in a mouse model of colitis-associated cancer.
KPV was associated with reduced tumour development in mice with functional PepT1. The same inhibitory effect was not observed in PepT1-knockout mice.
This supported the proposed importance of PepT1-mediated transport within that animal model.
The study does not show that KPV prevents colorectal cancer in humans. It did not test cancer prevention, recurrence or survival in people.
Animal tumour findings require particular caution
Cancer claims require extensive toxicology, pharmacology and controlled clinical evidence. An effect in an engineered mouse model should not be converted into a cancer-prevention statement.
KPV Nanoparticle and Targeted-Delivery Research
Engineered carriers have been investigated because a short peptide may be degraded or distributed poorly.
Researchers have loaded KPV into polymeric nanoparticles designed to target inflamed intestinal cells.
One 2017 study used hyaluronic-acid-functionalised nanoparticles containing KPV. The system was evaluated in intestinal cells and an experimental mouse model of ulcerative colitis.
Later studies combined KPV-based targeting with other experimental medicines or delivery materials.
These results apply to the complete engineered nanoparticle system, not simply to loose KPV powder.
Particle size, surface chemistry, peptide loading, release behaviour and the accompanying material can all influence the observed result.
KPV Research in Airway Epithelial Cells
Airway studies have been laboratory experiments rather than clinical asthma or lung-disease trials.
An investigation led by researchers at the University of Dundee examined KPV in immortalised human bronchial epithelial cells.
Cells were exposed to inflammatory signals and infectious-model stimuli. Researchers assessed NF-kappa B-related activity and chemokine signalling.
KPV reduced selected inflammatory signalling measurements through a mechanism that appeared different from the MC3R-dependent effect observed with another melanocortin peptide.
The use of human-derived cells does not make the experiment a human clinical study. The work did not test breathing, symptoms, lung function or exacerbations in patients.
No established treatment for asthma or post-viral illness
Airway-cell findings do not demonstrate that KPV treats asthma, chronic respiratory disease, long COVID or post-viral inflammation.
KPV Skin, Keratinocyte and Wound Research
Skin-related claims rely on cell models, cadaver tissue, animal work and research involving other melanocortin peptides.
Human Keratinocyte Cell Studies
Researchers have examined KPV signalling in cultured human keratinocytes.
One study did not detect a cyclic-AMP increase in response to KPV, supporting the view that its activity differs from conventional melanocortin-1 receptor signalling.
Cultured keratinocytes do not reproduce the full skin barrier, immune system, blood supply or clinical course of eczema and psoriasis.
Human Cadaver-Skin Transport
A 2017 study investigated KPV movement across dermatomed human cadaver skin.
Passive penetration was limited. Experimental iontophoresis and microporation increased delivery through the outer skin barrier.
This was an ex-vivo pharmaceutical-delivery experiment. It did not assess clinical effectiveness or safety in living participants.
Animal Wound Models
FDA identified rodent wound-related studies in the nonclinical KPV literature.
The agency concluded that human investigational studies would still be needed to determine whether KPV could have a role in skin wounds or ulcers.
Eczema and psoriasis claims remain unsupported
FDA found no clinical evidence for KPV in psoriasis, eczema, wound healing or another inflammatory skin condition.
KPV Antimicrobial Research
Laboratory antimicrobial findings do not establish treatment of bacterial or fungal infection.
A 2000 laboratory study examined alpha-MSH and KPV against Staphylococcus aureus and Candida albicans.
The researchers reported changes in colony formation, yeast viability and germ-tube formation under selected in-vitro conditions.
Related research has also investigated modified cysteine-linked melanocortin peptides against Candida species.
A modified linked peptide is not the same substance as ordinary KPV. Findings involving one should not be attributed automatically to the other.
No controlled human trial has established KPV as a treatment for candidiasis, bacterial infection, fungal overgrowth or an altered microbiome.
Do not replace established infection treatment
In-vitro antimicrobial activity does not establish an effective concentration in human tissue, clinical cure, resistance profile or safety alongside licensed antimicrobial medicines.
What Human Evidence Exists for KPV?
No administered-human evidence was identified by FDA in its 2026 assessment.
FDA searched published literature, clinical-trial records, drug databases and safety-reporting systems.
The agency did not identify a clinical study in which KPV free base or KPV acetate was administered to humans by any route.
It also found no human pharmacokinetic or pharmacodynamic study, no human case report and no identified human exposure dataset.
The human cadaver-skin experiment is not evidence of administration to a living person.
Studies using cultured cells originally obtained from human tissues are also not human clinical trials.
The absence of human studies means there is no established human absorption profile, distribution pattern, metabolism, half-life, dose-response relationship, therapeutic range or adverse-effect frequency.
No adverse-event reports does not mean no adverse effects
FDA found no KPV adverse-event cases, but it also found no organised human exposure evidence. Without regulated use and systematic surveillance, uncommon or delayed harms cannot be measured reliably.
KPV Peptide Evidence at a Glance
The available record supports laboratory interest but not medical or personal-use claims.
| Research Question | Evidence Type | Current Finding | Main Limitation |
|---|---|---|---|
| Is KPV a naturally occurring peptide fragment? | Sequence and biochemical evidence | Yes, it forms alpha-MSH residues 11–13 | Commercial material is synthetically produced and may differ in form |
| Does KPV activate classical melanocortin signalling? | Receptor and cell experiments | Conventional receptor activity was not consistently demonstrated | No single mechanism explains all observations |
| Can PepT1 transport KPV? | Human-derived cell lines and mouse research | Transport reported in selected intestinal and immune models | Human tissue exposure has not been established |
| Does KPV alter inflammatory signalling? | Cell experiments | NF-kappa B, MAPK and cytokine changes reported | Laboratory markers are not clinical outcomes |
| Does KPV affect experimental colitis? | DSS and TNBS mouse studies | Reduced inflammatory measurements reported | Mouse chemical-injury models differ from human IBD |
| Does KPV prevent colorectal cancer? | Colitis-associated cancer mouse model | PepT1-dependent tumour changes reported | No human cancer-prevention evidence |
| Does KPV affect airway inflammation? | Immortalised bronchial epithelial cells | Selected signalling changes reported | No patient or lung-function study |
| Does KPV treat skin conditions? | Cells, cadaver skin and animal research | Investigational findings only | No human eczema, psoriasis or wound-treatment trial identified |
| Does KPV have antimicrobial activity? | In-vitro organism studies | Activity reported under selected conditions | No clinical infection evidence |
| Is human pharmacokinetics known? | FDA evidence search | No | No administered-human study identified |
| Is long-term safety established? | Clinical and toxicology evidence | No | Major nonclinical and human evidence gaps |
| Is KPV authorised in the UK? | Regulatory-source review | No marketing authorisation identified | Online availability is not regulatory approval |
Important KPV Research Limitations
The current literature should not be used to make broad health or treatment claims.
- No administered-human clinical study was identified by FDA.
- No human pharmacokinetic study was identified.
- No human pharmacodynamic study was identified.
- No established human dose-response relationship exists.
- No validated human safety profile exists.
- No controlled trial supports use in inflammatory bowel disease.
- No controlled trial supports use in eczema or psoriasis.
- No controlled trial supports wound-healing claims.
- No controlled trial supports Candida or antimicrobial treatment claims.
- Most intestinal findings come from chemically induced mouse colitis.
- Mouse colitis does not reproduce the full biology of human IBD.
- Cell-line results do not reproduce a complete immune system.
- Cadaver-skin transport does not establish clinical topical delivery.
- Nanoparticle findings apply to the engineered carrier system tested.
- Different KPV chemical forms may be conflated.
- KPV is sometimes confused with KdPT or CKPV derivatives.
- Aggregate formation has not been adequately characterised.
- Long-term genotoxicity and carcinogenicity information is absent.
- Developmental and reproductive toxicology information is absent.
- Research-market products may not match published study material.
How KPV Research Material Should Be Analytically Tested
A three-residue sequence is simple in appearance but still requires complete chemical and batch-specific verification.
Intact Molecular Mass
Mass spectrometry should show an ion pattern consistent with the declared free peptide or salt form.
Tandem Mass Spectrometry
Fragment evidence should support the Lys-Pro-Val sequence and help exclude positional or sequence variants.
Free Acid or Amidated Form
Testing should distinguish H-Lys-Pro-Val-OH from KPV-NH2 and other modified derivatives.
Acetate Measurement
Acetate should be identified and quantified where the material is described as KPV acetate.
Net Peptide Assay
Peptide content should be measured rather than inferred from the total dried-material weight.
Related Substances
Chromatography should assess deletion sequences, incomplete coupling products, isomers and degradation compounds.
Lys-Pro Diketopiperazine
FDA identified Lys-Pro diketopiperazine as a major reported degradation product under several forced-degradation conditions.
Higher-Molecular-Weight Species
Orthogonal methods may be needed because reverse-phase HPLC does not necessarily identify every aggregate.
What a Meaningful KPV Certificate of Analysis Should Include
- Complete peptide name and Lys-Pro-Val sequence
- Confirmation of free-acid or amidated form
- Declared salt and counterion
- Observed intact molecular mass
- Tandem-MS sequence evidence
- Quantitative net peptide assay
- Chromatographic purity
- Named and unknown impurity results
- Assessment of Lys-Pro diketopiperazine
- Acetate content where applicable
- Water-content result
- Residual-solvent results
- Aggregation result or a clear testing limitation
- Finished-product batch number
- Testing-laboratory identity
- Analytical methods and acceptance criteria
- A clear statement of tests not performed
Why “99% HPLC” Is Not Enough
A chromatographic purity percentage does not prove the correct terminal groups, salt form, peptide amount, aggregate level, degradation profile or microbiological quality.
FDA described KPV free base and KPV acetate as insufficiently characterised because of inconsistent naming and missing information about impurities, aggregates and microbiological controls.
KPV Safety and Product-Quality Uncertainties
The absence of human exposure data prevents a reliable assessment of potential adverse effects.
No Human Safety Programme
FDA did not identify any clinical study assessing KPV safety by an oral, injectable, topical, nasal or other route.
Without controlled exposure, adverse-event frequency, severity, reversibility and dose relationship cannot be estimated.
Missing Nonclinical Toxicology
FDA did not identify dedicated acute-toxicity studies for KPV free base or KPV acetate.
It also did not identify repeat-dose toxicology, genotoxicity, developmental toxicology or reproductive-toxicity studies sufficient for human development.
Aggregation and Immunogenicity
Peptides can form larger associated structures during manufacture, formulation or storage.
Aggregates can change pharmacological behaviour and may increase the chance of immune recognition.
FDA found no human study evaluating KPV aggregation or immunogenicity and concluded that the potential risks remain unknown.
Endogenous-Peptide Context
KPV corresponds to part of a naturally occurring human peptide, but synthetic administration is not equivalent to normal local production within tissues.
Exposure level, route, concentration, impurities and duration can differ substantially from endogenous physiology.
Product-Quality Risks
- Incorrect amino-acid sequence
- KPV-NH₂ supplied instead of free-acid KPV
- Incorrect acetate content
- Incorrect peptide quantity
- Incomplete coupling products
- Sequence deletions or insertions
- Diketopiperazine formation
- Oxidative or hydrolytic degradation
- Aggregates
- Residual coupling reagents or solvents
- Unverified microbiological quality
- Unverified bacterial-endotoxin control
- Certificates unrelated to the finished batch
- Uncontrolled storage or transport
“Naturally occurring” does not prove safety
A naturally occurring sequence can still produce unpredictable effects when manufactured, concentrated, modified or administered outside its normal biological context.
FDA’s 2026 KPV Assessment
The document was prepared for an advisory meeting and should not be confused with a final agency decision.
FDA assessed KPV free base and KPV acetate for possible inclusion on the US section 503A Bulks List.
The agency identified inconsistent chemical naming, incomplete public characterisation and missing information concerning aggregates, impurities and microbiological controls.
FDA found no administered-human clinical study, no human pharmacokinetic study, no human case report and no human exposure data by any route.
It concluded that there was insufficient evidence to evaluate effectiveness for the nominated uses of wound healing and inflammatory conditions.
It also concluded that potential safety risks in humans remained unknown.
FDA staff stated that the balancing of the statutory criteria weighed against placing KPV free base or KPV acetate on the 503A Bulks List.
Status on 21 July 2026
The Pharmacy Compounding Advisory Committee meeting was scheduled for 23 and 24 July 2026. The staff briefing expressly stated that FDA would not make a final determination until the advisory process and reviews were completed.
KPV Regulation in the Peptides UK Market
Regulatory information checked on 21 July 2026.
No UK Marketing Authorisation Identified
No current UK marketing authorisation for a medicinal product containing KPV free peptide or KPV acetate was identified in the official product sources reviewed for this article.
KPV should not be presented as an approved treatment for inflammatory bowel disease, eczema, psoriasis, wounds, Candida, mast-cell disorders or another medical condition.
A product being available through an online catalogue does not mean that it has been assessed for safety, quality or efficacy by the MHRA.
How the MHRA Determines Whether a Product Is a Medicine
MHRA guidance states that a product may be medicinal when it is presented as preventing or treating disease.
A product can also be medicinal when it is intended to restore, correct or modify a physiological function through pharmacological, immunological or metabolic action.
The MHRA can consider explicit claims, implied claims, ingredient properties, intended use, packaging, websites, social-media content, advertisements and customer reviews.
Claims involving inflammatory bowel disease, eczema, psoriasis, immune regulation, infection, wound healing or intestinal repair could contribute to medicinal classification.
A “Research Use Only” label does not necessarily determine status when the wider commercial presentation encourages personal administration.
Advertising Restrictions
Regulation 279 of the Human Medicines Regulations restricts advertising medicinal products where the necessary marketing authorisation, registration or certificate is not in force.
This section provides general regulatory education and does not constitute legal advice.
KPV Peptide and Competitive Sport
A substance does not need to be named individually before it can create an anti-doping risk.
KPV was not identified by name in the 2026 World Anti-Doping Agency Prohibited List reviewed for this article.
However, section S0 prohibits pharmacological substances that are not addressed elsewhere in the list and have no current approval by a governmental regulatory health authority for human therapeutic use.
Because KPV has no identified authorised human medicinal use, an athlete should not assume that it is permitted.
Athletes should obtain an authoritative ruling from UK Anti-Doping, their international federation or another competent anti-doping body before exposure to any experimental peptide.
Supplier assurances and “Research Use Only” wording do not prevent an anti-doping violation.
Common KPV Peptide Claims Examined
Most commercial claims extend beyond the experimental evidence.
“KPV is a proven anti-inflammatory peptide.”
KPV altered inflammatory signalling in cells and reduced selected measurements in mouse models.
No controlled human exposure study was identified, so clinical effectiveness has not been established.
“KPV treats ulcerative colitis and Crohn’s disease.”
KPV has been studied in chemically induced mouse colitis.
No human inflammatory-bowel-disease trial was identified.
“KPV heals leaky gut.”
Intestinal-cell and animal studies examined transport, inflammatory markers and mucosal injury.
“Leaky gut” is used inconsistently online, and no controlled human KPV trial established treatment of intestinal permeability.
“KPV treats eczema and psoriasis.”
Skin-cell and related melanocortin research provide mechanistic interest.
FDA found no human KPV evidence for eczema, psoriasis or another inflammatory skin condition.
“KPV kills Candida.”
In-vitro experiments reported antimicrobial effects against Candida albicans under selected conditions.
No human candidiasis-treatment study was identified.
“KPV heals wounds.”
Wound-related animal studies and skin-delivery experiments exist.
No human wound-healing or ulcer trial established effectiveness.
“KPV cannot affect pigmentation.”
KPV lacks the central receptor-binding motif associated with classical alpha-MSH pigmentation signalling.
This mechanistic distinction does not amount to a complete human safety study of every KPV formulation.
“Because KPV is endogenous, it cannot be immunogenic.”
The sequence occurs within a natural human peptide.
Synthetic impurities, aggregates, modified forms and altered exposure can still create immune-related risk.
“KPV has no reported side effects.”
FDA found no adverse-event reports associated with administered KPV.
It also found no clinical exposure studies, so the absence of reports cannot define safety.
“A 99% COA proves the vial is suitable for use.”
Chromatographic purity may support one aspect of chemical assessment.
It does not prove the correct form, quantity, aggregate level, sterility, endotoxin control or human suitability.
KPV Compared With Related Melanocortin Peptides
Similar sequences and names should not be treated as interchangeable evidence.
| Peptide | Basic Identity | Main Research Context | Important Distinction |
|---|---|---|---|
| Alpha-MSH | Natural 13-residue melanocortin peptide | Pigmentation, inflammation and melanocortin receptors | Contains the complete receptor-binding pharmacophore |
| KPV | Lys-Pro-Val | Inflammatory signalling, PepT1 and preclinical models | C-terminal three-residue alpha-MSH fragment |
| KPV-NH₂ | Amidated Lys-Pro-Val derivative | Commercial and limited derivative research | Not identical to natural free-acid KPV |
| KdPT | Lys-D-Pro-Thr | Experimental intestinal and inflammatory research | Different third residue and D-amino-acid stereochemistry |
| CKPV derivatives | Cysteine-containing modified peptides | Antimicrobial and stability research | Modified structures with different molecular properties |
| Melanotan I | Modified full-length alpha-MSH analogue | Pigmentation and photosensitivity research | Thirteen residues and strong MC1R activity |
How to Assess KPV and Peptides UK Evidence Critically
Use this checklist before accepting a scientific, quality or commercial claim.
- Does the source state the Lys-Pro-Val sequence?
- Is the peptide free-acid KPV or KPV-NH₂?
- Is acetate a counterion or a covalent modification?
- Is KPV being confused with KdPT?
- Is a CKPV derivative being presented as ordinary KPV?
- Was the research performed in cells, mice or humans?
- Was KPV administered to a living human participant?
- Was the model DSS or TNBS chemical colitis?
- Did the study use a nanoparticle formulation?
- Was PepT1 expression experimentally confirmed?
- Was the outcome a cytokine marker or a clinical endpoint?
- Was human pharmacokinetics measured?
- Was safety monitored systematically?
- Were aggregates evaluated?
- Were degradation products measured?
- Was Lys-Pro diketopiperazine assessed?
- Does the COA match the finished batch?
- Does the source distinguish cell-line research from a clinical trial?
- Are antimicrobial findings being converted into infection claims?
- Is the claimed purpose authorised in the UK?
- Is the source selling the product it describes?
Medical and Editorial Review
This final article has been reviewed for medical context, evidence presentation, patient safety language and editorial clarity by the multidisciplinary panel below.
The reviewers and contributors are identified to provide clear authorship and accountability. Their inclusion does not represent endorsement of any research product, supplier, personal use, treatment claim or commercial statement discussed in this article.
Dr Laura Geige
Medical Director and Senior Aesthetics Practitioner at It’s Me & You Clinic, with a background in dentistry, medical aesthetics and cosmetic dermatology.
Read professional profile
Dr Rimas Geiga
Medical doctor with a special interest in nutritional sciences, dietology, metabolic health and evidence based preventative care.
Read professional profile
Dr Snieguole Geige
Dentist and medical doctor with experience across healthcare, preventative medicine and patient centred clinical standards.
Read professional profile
Dr Giedre Narkiene
Medical doctor and board certified dermatologist with expertise in medical and cosmetic dermatology, skin health and patient safety.
Read professional profile
Dr Veronika Matutyte
Medical doctor with training and professional experience in gerontology and healthcare management across clinical and hospital settings.
Read professional profile
Livija Samušienė
Qualified cosmetologist with a Bachelor of Health Sciences in cosmetology and a professional interest in skin health, acne and evidence based aesthetic care.
Read professional profileKPV Peptide UK Frequently Asked Questions
Evidence-led answers about KPV identity, laboratory research, safety and UK regulation.
What is KPV peptide?
KPV is the tripeptide lysine-proline-valine and forms the final three residues of alpha-melanocyte-stimulating hormone.
What does KPV stand for?
K, P and V are the single-letter codes for lysine, proline and valine.
Is KPV naturally occurring?
The sequence occurs naturally as part of alpha-MSH. Commercial research KPV is synthetically manufactured.
Is KPV the same as alpha-MSH?
No. Alpha-MSH contains 13 amino acids, while KPV contains only its final three residues.
What is the KPV sequence?
The commonly described free peptide is H-Lys-Pro-Val-OH.
What is KPV acetate?
KPV acetate is KPV associated with acetate as a salt or counterion. It has a different total molecular weight from the free peptide.
Is KPV acetate the same as acetylated KPV?
No. An acetate counterion is not the same as a covalent acetyl group attached to the peptide.
Is KPV-NH₂ the natural form?
No. KPV-NH₂ is a C-terminally amidated derivative. Natural alpha-MSH ends with valine as a free carboxylic acid.
Is KPV the same as KdPT?
No. KdPT contains lysine, D-proline and threonine and is a distinct synthetic tripeptide.
How is KPV thought to affect inflammatory signalling?
Cell studies report changes involving NF-kappa B, MAP-kinase pathways and selected cytokines. No single complete mechanism has been confirmed in humans.
What is PepT1?
PepT1 is a transporter that carries selected dipeptides and tripeptides into cells. It has transported KPV in intestinal and immune-cell research systems.
Has KPV been studied for inflammatory bowel disease?
It has been studied in intestinal cells and chemically induced mouse-colitis models. No human IBD treatment trial was identified.
Does KPV treat ulcerative colitis?
No established treatment claim can be made. Mouse-model findings do not demonstrate effectiveness in people with ulcerative colitis.
Does KPV treat Crohn’s disease?
No controlled human evidence was identified for Crohn’s disease.
Has KPV been studied for eczema or psoriasis?
Skin-cell and related preclinical studies exist, but FDA found no human KPV clinical evidence for eczema or psoriasis.
Does KPV heal wounds?
Animal and laboratory wound-related research exists. Human wound-healing effectiveness has not been established.
Does KPV kill Candida?
In-vitro experiments reported effects against Candida albicans under selected conditions. No human candidiasis-treatment study was identified.
Does KPV have pigmentation effects?
KPV lacks the principal melanocortin-receptor-binding motif associated with alpha-MSH pigmentation signalling. This mechanistic point is not a substitute for human safety data.
Has KPV been administered to humans in clinical studies?
FDA stated in its 2026 assessment that it had not identified human exposure data by any route.
Are KPV side effects known?
No reliable human adverse-effect profile exists because controlled human exposure studies were not identified.
What did FDA conclude about KPV in 2026?
FDA staff found major evidence, safety and characterisation gaps and stated that the available criteria weighed against inclusion on the 503A Bulks List. The advisory meeting had not yet occurred when this article was reviewed.
Is KPV approved in the UK?
No current UK marketing authorisation for a KPV medicine was identified.
Does “Research Use Only” settle the UK legal position?
No. The MHRA may consider the ingredient, pharmacological properties, intended purpose, claims and complete commercial presentation.
Is KPV prohibited in competitive sport?
KPV was not identified by name on the reviewed 2026 WADA list, but non-approved pharmacological substances may fall within section S0. Athletes should seek an official ruling.
Does 99% HPLC prove a KPV vial is authentic?
No. It does not prove the correct terminal form, counterion, amount, aggregate level, degradation profile or microbiological quality.
What should a KPV COA include?
It should include sequence identity, terminal groups, salt form, molecular mass, peptide assay, impurity profile, acetate, degradation and batch-specific information.
Does this article provide dosing or administration instructions?
No. It does not provide preparation, reconstitution, dosing, injection, oral-use, topical-use, nasal-use or personal-experimentation guidance.
Key Takeaways
- KPV is the tripeptide lysine-proline-valine.
- It corresponds to residues 11 to 13 of alpha-MSH.
- KPV does not contain the principal receptor-binding motif of the complete parent hormone.
- Cell research has examined NF-kappa B, MAPK and cytokine signalling.
- PepT1 can transport KPV in selected intestinal and immune-cell models.
- Mouse studies report changes in experimental colitis and colitis-associated cancer.
- Airway, skin, wound and antimicrobial research remains preclinical.
- FDA identified no human exposure data by any route.
- No established human pharmacokinetic or safety profile exists.
- KPV free peptide, KPV acetate and KPV-NH₂ are not chemically identical.
- FDA staff identified major characterisation, effectiveness and safety gaps in 2026.
- No UK marketing authorisation was identified.
- A purity percentage alone cannot establish identity, stability or human suitability.
Relevant It’s Me & You Clinic Peptides UK Resources
Explore related evidence-led research articles and clinical contributor profiles.
KLOW Peptide UK
Review why KPV evidence should not be transferred automatically to a multi-component research blend.
Browse related peptide guidesMelanotan I UK
Compare the short KPV fragment with a complete modified alpha-MSH analogue.
Browse related peptide guidesResearch Peptides UK
Browse the wider educational series on peptide identity, experimental evidence, analytical testing and UK regulation.
Browse the Peptides UK education libraryDr Giedre Narkiene
Learn more about the clinic’s dermatology adviser and evidence-based approach to skin science.
View Dr Giedre Narkiene’s profileReferences
- US Food and Drug Administration. FDA evaluation of KPV-related bulk drug substances, KPV free base and KPV acetate. Pharmacy Compounding Advisory Committee briefing document dated 12 May 2026. FDA KPV briefing document
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of 22 April 2026. FDA safety information
- US Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting scheduled for 23 and 24 July 2026. FDA advisory meeting page
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. doi:10.1053/j.gastro.2007.10.026. PMID: 18061177. PubMed record
- Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324–331. doi:10.1002/ibd.20334. PMID: 18092346. PubMed record
- Viennois E, et al. Critical role of PepT1 in promoting colitis-associated cancer and the experimental use of KPV in wild-type and PepT1-knockout mice. 2016. PMID: 27458604. PubMed record
- Xiao B, Xu Z, Viennois E, et al. Orally targeted delivery of tripeptide KPV using hyaluronic-acid-functionalised nanoparticles in experimental colitis. 2017. PMID: 28143741. PubMed record
- Zhang D, et al. PepT1-targeted nanodrug based on co-assembly of an anti-inflammatory peptide and immunosuppressant in experimental colitis. Frontiers in Pharmacology. 2024;15:1442876. Full-text article
- Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. International Journal of Physiology, Pathophysiology and Pharmacology. 2012;4(2). PMID: 22837805. PubMed record
- Elliott RJ, et al. Alpha-melanocyte-stimulating hormone, MSH 11–13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. 2004. PMID: 15102092. PubMed record
- Pawar K, Kolli CS, Rangari VK, Babu RJ. Transdermal iontophoretic delivery of lysine-proline-valine peptide across microporated human skin. Journal of Pharmaceutical Sciences. 2017;106(7):1814–1820. doi:10.1016/j.xphs.2017.03.017. PMID: 28343991. PubMed record
- Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH peptides. Journal of Leukocyte Biology. 2000;67(2):233–239. doi:10.1002/jlb.67.2.233. PMID: 10670585. PubMed record
- Medicines and Healthcare products Regulatory Agency. Borderline products: how to tell if your product is a medicine. Updated 2 July 2026. MHRA guidance
- Medicines and Healthcare products Regulatory Agency. A guide to what is a medicinal product. Guidance Note 8, revised May 2026. MHRA Guidance Note 8
- Human Medicines Regulations 2012, Regulation 279. Legislation.gov.uk
- World Anti-Doping Agency. 2026 Prohibited List. WADA 2026 Prohibited List
- International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures. ICH analytical guideline
- UK Accreditation Service. Laboratory accreditation and ISO/IEC 17025. UKAS guidance
